Your session is about to expire
← Back to Search
UGN-102 for Bladder Cancer (ATLAS Trial)
ATLAS Trial Summary
This trial is testing a new treatment for patients with low grade bladder cancer. The new treatment is mitomycin (UGN-102) given as an intravesical solution with or without TURBT.
- Bladder Cancer
ATLAS Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 2 trial • 63 Patients • NCT03558503ATLAS Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the FDA greenlit UGN-102 for therapeutic use?
"UGN-102 has been studied in multiple Phase 3 trials, which is the gold standard for clinical research. This gives us confidence that it is a safe medication."
What is the precedent for UGN-102 in medical research?
"The study of UGN-102 began in 2007 at the Labbafinejad Medical Center in Tehran. So far, there have been 58 completed studies and 45 ongoing trials. Many of these ongoing studies are taking place in San Antonio, Texas."
What are the most common maladies that UGN-102 is effective against?
"UGN-102 is most commonly used to treat cervical cancer. However, it has also been found useful in treating other conditions such as low-grade upper tract urothelial cancer (lg-utuc), mesotheliomas, and glaucoma."
How many different facilities are helping to manage this clinical trial?
"There are 35 locations enrolling patients for this clinical trial, which are situated in cities such as San Antonio, Santa Monica and Bloomfield. To limit travel if you choose to enroll, it is best to select a site near you."
Share this study with friends
Copy Link
Messenger